Breaking News, Trials & Filings

FSD Pharma Gets Go Ahead for Phase IIa COVID-19 Trial

To evaluate FSD-201 to treat COVID-19; anti-inflammatory properties aim to avoid the cytokine storm.

By: Contract Pharma

Contract Pharma Staff

FSD Pharma Inc. received approval from the U.S. FDA to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters